Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time
December 2021: The protection offered by the Oxford-Astra Zeneca Covid-19 vaccine declines after three months of receiving two doses, a study says.
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil
The findings – drawn from datasets in two countries – suggest that booster programmes are needed to help maintain protection from severe disease in those vaccinated with Oxford-Astra Zeneca, experts say.
Fivefold increase in risk of hospitalisation or death after five months
Researchers from Scotland and Brazil analysed data for two million people in Scotland and 42 million people in Brazil who had been vaccinated with the Oxford-Astra Zeneca vaccine.
In Scotland, when compared with two weeks after receiving a second dose, there was approximately a fivefold increase in the chance of being hospitalised or dying from Covid-19 nearly five months after being double vaccinated.
The decline in effectiveness begins to first appear at around three months, when the risk of hospitalisation and death is double that of two weeks after the second dose, experts say.
The risk increases threefold just short of four months after the second vaccine dose. Similar numbers were seen for Brazil.
Researchers were able to compare data between Scotland and Brazil as they had a similar interval between doses – 12 weeks – and initial prioritisation of who was vaccinated – people at highest risk of severe disease and healthcare workers.
The dominant variant was different in each country during the study period – Delta in Scotland and Gamma in Brazil – meaning the decline in effectiveness is likely because of vaccine waning and the impact of variants.
The study, published in The Lancet, also estimated vaccine effectiveness at similar fortnightly intervals by comparing outcomes of people who have been jabbed with those who are unvaccinated.
But experts warned these figures should be treated with caution because it is becoming harder to compare unvaccinated people to vaccinated people with similar characteristics, particularly among older age groups where so many people are now vaccinated.
Vaccines have been a key tool in fighting the pandemic, but waning in their effectiveness has been a concern for a while. By identifying when waning first starts to occur in the Oxford-Astra Zeneca vaccine, it should be possible for governments to design booster programmes that can ensure maximum protection is maintained.
If eligible for a booster and you have not had yet had one, I would highly recommend that you book one soon.
EAVE II study
The study is part of the EAVE II project, which uses anonymised linked patient data in Scotland to track the pandemic and the vaccine roll out in real time.
The research team included scientists from the Universities of Edinburgh, Glasgow, Aberdeen, Strathclyde, and St Andrew’s; Public Health Scotland; Victoria University of Wellington; Fiocruz; Universidade do Estado do Rio de Janeiro and Universidade Federal de Bahia.
Our analyses of national datasets from both Scotland and Brazil suggest that there is considerable waning of effectiveness for the Oxford AstraZeneca vaccine, with protection against severe Covid-19 falling over time.
We studied two million people in Scotland and over 42 million people in Brazil who had received two doses of the Oxford-AstraZeneca vaccine. More than four months after receiving a second dose, the risk of experiencing either a Covid-19 hospitalisation or death was approximately five times greater than the period of maximum vaccine protection after accounting for changes in infection rates and a range of other factors.
Our work highlights the importance of getting boosters, even if you’ve had two doses of the Oxford AstraZeneca vaccine, as soon as you are able to.
The study was funded by the Medical Research Council, UK Research and Innovation Industrial Strategy Challenge Fund, the National Institute for Health Research and Health Data Research UK (HDR UK), and was supported by the Scottish Government.
Additional support was provided through the Scottish Government Director-General Health and Social Care, and the UKRI COVID-19 National Core Studies Data and Connectivity programme led by HDR UK.
This plain English summary and infographic were created with the support and feedback of the EAVE II Patient Advisory Group (PAG). This summary in particular was reviewed by PAG members David W and Hameed K.
To learn more visit : Our EAVE II Patient Advisory Group (PAG) | The University of Edinburgh